Ahammune Biosciences Pvt. Ltd.

About

Ahammune Biosciences Pvt. Ltd. is a biotechnology company based in Pune, India, founded in 2016. The company focuses on drug discovery for immune-mediated and autoimmune skin diseases, particularly vitiligo. Ahammune aims to develop therapeutic solutions that restore the skin's immune system and address chronic skin conditions with unmet needs. Their proprietary small molecules are designed to correct cellular pathways, promoting long-term skin health with minimal side effects. The company's lead candidate, AB1001 gel, is a topical treatment for vitiligo that has completed Phase 1 clinical trials, showing a safe profile for use. Ahammune operates with a team of experts in dermatology, molecular biology, and drug development, and has raised $5 million in Series A funding. The company holds three patents and is positioned to tap into the growing global vitiligo market, which is projected to reach $4.3 billion by 2027.